Translational Risk Matrix

Where preclinical-to-clinical translation is most uncertain across the PeptideStacks library.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Translational risk is the probability that a finding established in a cell line or animal model does not reproduce in humans. Across drug development as a whole the failure rate is high, and for peptide-class compounds it is particularly high because species differ in receptor distribution, immunogenicity, and pharmacokinetics. A compound is rated low only when it has UK-approved human evidence for the specific use described; moderate when there is some human data but it is limited or indirect; high when the evidence base is predominantly preclinical. Read this matrix alongside animal vs human peptide research and in vitro evidence limitations.

	Compound / stack	Main study type	Human data	Translational risk	Reason
Peptide	AOD-9604 — Growth Hormone C-terminal Lipolytic Fragment	animal	no	high	Lack of human data; published evidence is predominantly preclinical.
Peptide	BPC-157 — Body Protection Compound 157	animal	no	high	Lack of human data; published evidence is predominantly preclinical.
Peptide	GHK-Cu — Copper Tripeptide-1	animal	no	high	Lack of human data; published evidence is predominantly preclinical.
Peptide	Humanin — Mitochondrial-Derived 24-Amino-Acid Peptide	animal	no	high	Lack of human data; published evidence is predominantly preclinical.
Peptide	KPV — α-MSH(11-13) C-Terminal Anti-Inflammatory Tripeptide	animal	no	high	Lack of human data; published evidence is predominantly preclinical.
Peptide	LL-37 — Human Cathelicidin Antimicrobial Peptide	animal	no	high	Lack of human data; published evidence is predominantly preclinical.
Peptide	MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-c	animal	no	high	Lack of human data; published evidence is predominantly preclinical.
Peptide	SS-31 (Elamipretide) — Cardiolipin-Targeted Mitochondrial Peptide	animal	no	high	Lack of human data; published evidence is predominantly preclinical.
Peptide	TB-500 — Thymosin β-4 (1-4) Synthetic Fragment	animal	no	high	Lack of human data; published evidence is predominantly preclinical.
Stack	BPC-157 + GHK-Cu — Research Evidence Review: Follicular Mechanisms & Evidence Limits	animal	no	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	BPC-157 + KPV + Thymosin α-1 — Research Evidence Review: Immune & Mucosal Mechanisms	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	BPC-157 + TB-500 + GHK-Cu — Research Evidence Review: Tissue-Repair & Remodelling Mechanisms	mixed	limited	high	Direct combination evidence is limited (mostly preclinical / small-trial).
Stack	BPC-157 + TB-500 — Research Evidence Review: Tissue-Repair Mechanisms & Translational Limits	mixed	limited	high	Direct combination evidence is limited (mostly preclinical / small-trial).
Stack	CJC-1295 + Ipamorelin + Tesamorelin — Research Evidence Review: GH Axis Mechanisms & Study Limitations	mixed	limited	high	Direct combination evidence is limited (mostly preclinical / small-trial).
Stack	Cerebrolysin + Semax — Research Evidence Review: Neuropeptide & BDNF-Axis Mechanisms	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	DSIP + Selank — Research Evidence Review: Sleep & Anxiolytic Mechanisms	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	Epitalon + Humanin + MOTS-c — Research Evidence Review: Mitochondrial & Telomeric Mechanisms	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	Epithalon + Thymalin — Research Evidence Review: Khavinson Bioregulator Mechanisms	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	GHK-Cu + TB-500 — Research Evidence Review: Dermal Remodelling Mechanisms	animal	no	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	Ipamorelin + CJC-1295 + BPC-157 — Research Evidence Review: GH Axis + Tissue-Repair Mechanisms	mixed	limited	high	Direct combination evidence is limited (mostly preclinical / small-trial).
Stack	KPV + LL-37 — Research Evidence Review: Mucosal & Antimicrobial Mechanisms	animal	no	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	MOTS-c + AOD-9604 — Research Evidence Review: Mitochondrial & Lipolytic Mechanisms	animal	no	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	Melanotan II + Bremelanotide — Research Evidence Review: Melanocortin Mechanisms & Safety Signals	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	PT-141 + Kisspeptin-10 — Research Evidence Review: Melanocortin & Reproductive-Axis Mechanisms	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	SS-31 + Humanin — Research Evidence Review: Mitochondrial Mechanisms	animal	no	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	SS-31 + MOTS-c — Research Evidence Review: Mitochondrial Cardiovascular Mechanisms	animal	no	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	Semax + Selank + Pinealon — Research Evidence Review: Neuropeptide Mechanisms & Translational Limits	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	TB-500 + BPC-157 — Research Evidence Review: Tendon Repair Mechanisms & Study Models	mixed	limited	high	Direct combination evidence is limited (mostly preclinical / small-trial).
Stack	Tesamorelin + AOD-9604 — Research Evidence Review: Visceral Adipose Research Context	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Stack	Tirzepatide + Retatrutide + AOD-9604 — Research Evidence Review: Incretin & Lipolytic Mechanisms (UK POM sensitivity)	mixed	indirect	high	No direct combination studies; mechanism is inferred from monotherapy literature.
Peptide	Cerebrolysin — Porcine-Brain Neuropeptide Preparation	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	CJC-1295 — GHRH(1-29) Analogue (no DAC / DAC variants)	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	DSIP — Delta Sleep-Inducing Peptide	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	Epitalon — Pineal Tetrapeptide Bioregulator	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	Ipamorelin — Selective Growth Hormone Secretagogue	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	Kisspeptin-10 — GnRH-Axis Hypothalamic Decapeptide	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	Melanotan II — Broad-Spectrum α-MSH Analogue	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	Pinealon — Pineal Tripeptide Bioregulator	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	PT-141 (Bremelanotide) — MC4R-Selective Melanocortin Agonist	mixed	yes	moderate	Approved as a medicine in another jurisdiction; not licensed in the UK.
Peptide	Retatrutide — Triple GIP/GLP-1/Glucagon Receptor Agonist	mixed	yes	moderate	Approved as a medicine in another jurisdiction; not licensed in the UK.
Peptide	Selank — Tuftsin-Derivative Anxiolytic Heptapeptide	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	Semax — ACTH(4-10) Heptapeptide Nootropic	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	Tesamorelin — Stabilised GHRH Analogue (EGRIFTA)	mixed	yes	moderate	Approved as a medicine in another jurisdiction; not licensed in the UK.
Peptide	Thymalin — Thymic Peptide Complex Bioregulator	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	Thymosin α-1 — Thymic Immunomodulatory Peptide (Zadaxin / Thymalfasin)	mixed	limited	moderate	Human translation outside approved indications is not established.
Peptide	Tirzepatide — Dual GIP/GLP-1 Receptor Agonist (Mounjaro / Zepbound)	mixed	yes	low	Off-label or off-indication use is not within the licensed evidence base.